Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768428 | 0.91 | MLYCD (0.34) | MLYCDTSHR | |
| SCHEMBL3530650 | 0.79 | NR4A2 (0.37) | MLYCDTSHR | |
| SCHEMBL3535482 | 0.77 | CA12 (0.35) | MLYCD | |
| SCHEMBL3530598 | 0.73 | MLYCD (0.38) | MLYCD | |
| SCHEMBL13255023 | 0.73 | MLYCD (0.32) | MLYCD | |
| SCHEMBL4767330 | 0.70 | MLYCD (0.35) | MLYCD | |
| SCHEMBL3537718 | 0.67 | ALOX5 (0.34) | — | |
| SCHEMBL68934 | 0.63 | TSHR (0.46) | TSHR | |
| SCHEMBL19085521 | 0.62 | TSHR (0.56) | MLYCDTSHR | |
| SCHEMBL4765220 | 0.62 | MAPK8 (0.45) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1732933-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097805-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | PCSK9, LIPC, APOB | MLYCD 571/4885TSHR 1221/4885ADORA2B 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.